Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL2113294 | 1.00 | SLC7A5 (0.47) | SLC7A5NOS2NOS3NOS1MEN1 | |
| Valine SCHEMBL28486680 | 1.00 | SLC7A5 (0.47) | SLC7A5NOS2NOS3NOS1MEN1 | |
| Valine SCHEMBL2543573 | 0.97 | SLC7A5 (0.50) | SLC7A5NOS2NOS3NOS1MEN1 | |
| Valine SCHEMBL137917 | 0.97 | SLC7A5 (0.50) | SLC7A5NOS2NOS3NOS1MEN1 | |
| Valine SCHEMBL2543574 | 0.97 | SLC7A5 (0.50) | SLC7A5NOS2NOS3NOS1MEN1 | |
| Valine SCHEMBL137916 | 0.97 | SLC7A5 (0.50) | SLC7A5NOS2NOS3NOS1MEN1 | |
| Valine SCHEMBL2256563 | 0.97 | SLC7A5 (0.50) | SLC7A5NOS2NOS3NOS1MEN1 | |
| Valine SCHEMBL28494584 | 0.95 | SLC7A5 (0.48) | SLC7A5NOS2NOS3NOS1MEN1 | |
| Valine SCHEMBL3048383 | 0.93 | SLC7A5 (0.41) | SLC7A5NOS2NOS3NOS1MEN1 | |
| Valine SCHEMBL4612496 | 0.93 | SLC7A5 (0.41) | SLC7A5NOS2NOS3NOS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020234461-A1 | ANTIBODY DRUG CONJUGATES WITH CLEAVABLE LINKERS | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2020-11-26 | — | — | WO | claimed |
| EP-0767799-A4 | A 24 KILODALTON CYTOPLASMIC PROTEASE ACTIVATING DNA FRAGMENTATION APOPTOSIS | PANORAMA RES INC (US) | 1997-06-04 | — | — | EP | claimed |
| EP-0767799-A1 | A 24 KILODALTON CYTOPLASMIC PROTEASE ACTIVATING DNA FRAGMENTATION APOPTOSIS | PANORAMA RESEARCH, INC. (US) | 1997-04-16 | — | — | EP | claimed |
| US-5605826-A | PREPARING CYTOPLASMIC EXTRACT OF MAMMALIAN CELLS PRETREATED WITH APOPTOSIS INDUCING AGENT, ISOLATING PROTEASE USING AFFINITY COLUMN HAVING IMMOBILIZED PROTEASE INHIBITOR, PURIFYING APOPTOTIC PROTEASE USING HEPARIN-SEPHAROSE COLUMN | PANORAMA RESEARCH, INC. (US) | 1997-02-25 | — | — | US | claimed |
| WO-1995034576-A1 | A 24 KILODALTON CYTOPLASMIC PROTEASE ACTIVATING DNA FRAGMENTATION APOPTOSIS | PANORAMA RESEARCH, INC. (US) | 1995-12-21 | — | — | WO | claimed |
| US-20240165257-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-05-23 | — | — | US | disclosed |
| WO-2024094688-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-05-10 | — | — | WO | disclosed |
| EP-3218013-B1 | MOLECULAR PROBES FOR DETECTING GRAM-NEGATIVE BACTERIA IN VITRO AND IN VIVO | UNIV COURT UNIV OF EDINBURGH (GB) | 2024-04-17 | — | — | EP | disclosed |
| US-20240108739-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | PHI PHARMA SA (CH) | 2024-04-04 | — | — | US | disclosed |
| EP-4308169-A2 | B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES | Heidelberg Pharma Research GmbH (DE) | 2024-01-24 | — | — | EP | disclosed |
| US-20230355792-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-4262879-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | Phi Pharma SA (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-10648979-B2 | Molecular probes for detecting gram-negative bacteria in vitro and in vivo | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-05-12 | — | — | US | disclosed |
| WO-2019197654-A1 | TARGETED AMATOXIN CONJUGATE FOR THE TREATMENT OF SOLID TUMORS | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2019-10-17 | — | — | WO | disclosed |
| US-20180120314-A1 | FLUORESCENT POLYBRANCHED PROBES FOR DETECTING BACTERIA AND/OR FUNGI IN VITRO AND IN VIVO | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2018-05-03 | — | — | US | disclosed |
| EP-3218013-A1 | MOLECULAR PROBES FOR DETECTING GRAM-NEGATIVE BACTERIA IN VITRO AND IN VIVO | The University Court Of The University of Edinburgh (GB) | 2017-09-20 | — | — | EP | disclosed |
| EP-3218014-A1 | FLUORESCENT POLYBRANCHED PROBES FOR DETECTING BACTERIA AND/OR FUNGI IN VITRO AND IN VIVO | The University Court Of The University of Edinburgh (GB) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016075481-A1 | FRET MOLECULAR PROBES WITH CLEAVABLE LINKERS FOR DETECTING BACTERIA AND/OR FUNGI IN VITRO AND IN VIVO | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016075483-A1 | MOLECULAR PROBES FOR DETECTING GRAM-NEGATIVE BACTERIA IN VITRO AND IN VIVO | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016075484-A1 | FLUORESCENT POLYBRANCHED PROBES FOR DETECTING BACTERIA AND/OR FUNGI IN VITRO AND IN VIVO | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108739-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | CD44, CSGALNACT1, LGALS3BP | SLC7A5 876/4885NOS2 4725/4885NOS3 4593/4885 |
| US-20230355792-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | CD47, ANXA5, MTX1 | SLC7A5 1278/4885NOS2 1936/4885NOS3 2247/4885 |
| US-10648979-B2 | Molecular probes for detecting gram-negative bacteria in vitro and in vivo | PGLS, BPGM, MB | SLC7A5 946/4885NOS2 4035/4885NOS3 4255/4885 |
| US-20240165257-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | GUCY1B2, MTX2, GUCY1A2 | SLC7A5 1909/4885NOS2 2929/4885NOS3 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.